A method of performing a chemical reaction includes reacting a compound selected from the group consisting of an organohalide and an organo-pseudohalide, and a protected organoboronic acid represented by formula (I) in a reaction mixture:
R.sup.1—B-T  (I);
where R.sup.1 represents an organic group, T represents a conformationally rigid protecting group, and B represents boron having sp.sup.3 hybridization. When unprotected, the corresponding organoboronic acid is unstable by the boronic acid neat stability test. The reaction mixture further includes a base having a pK.sub.B of at least 1 and a palladium catalyst. The method further includes forming a cross-coupled product in the reaction mixture.

Biomass derived benzophenone derivatives, and methods of making and using the same, are described. In accordance with the present disclosure, biomass derived benzophenone derivatives are useful as visible light photoinitiators.

Biomass derived benzophenone derivatives, and methods of making and using the same, are described. In accordance with the present disclosure, biomass derived benzophenone derivatives are useful as visible light photoinitiators.

A method of etherifying glycols or other diols by employing renewable reagents is disclosed. In particular, the method involves contacting a diol with an alkylating agent in an alcoholic solvent, catalyzed with a catalyst (carbonic acid) generated in situ (from CO.sub.2). The mono- and di-ether products can serve as valued precursors to an array of renewable surfactants, dispersants, and lubricants, among others.

A method of etherifying glycols or other diols by employing renewable reagents is disclosed. In particular, the method involves contacting a diol with an alkylating agent in an alcoholic solvent, catalyzed with a catalyst (carbonic acid) generated in situ (from CO.sub.2). The mono- and di-ether products can serve as valued precursors to an array of renewable surfactants, dispersants, and lubricants, among others.

A bisfuran dihalide having a structure represented by the following formula (1): ##STR00001##
wherein R.sup.1 is a divalent hydrocarbon group represented by —CR.sup.2R.sup.3— (wherein each of R.sup.2 and R.sup.3 independently represents a hydrogen atom or a monovalent hydrocarbon group, and R.sup.2 and R3 may together form a cyclic structure), or a carbonyl group (—C(═O)—); and each X independently represents a halogen atom.

A bisfuran dihalide having a structure represented by the following formula (1): ##STR00001##
wherein R.sup.1 is a divalent hydrocarbon group represented by —CR.sup.2R.sup.3— (wherein each of R.sup.2 and R.sup.3 independently represents a hydrogen atom or a monovalent hydrocarbon group, and R.sup.2 and R3 may together form a cyclic structure), or a carbonyl group (—C(═O)—); and each X independently represents a halogen atom.

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

An improved process for acid-catalyzed acylation using water-tolerant Lewis acid catalysts is described. The method involves reacting a reduction products of 5-(hydroxylmethyl)-furfural (HMF), in particular either furan-2,5-dimethanol (FDM) or bis-2,5-(hydroxymethyl)-tetrahydrofuran (bHMTHFs), with an excess of an organic acid in the presence of a Lewis acid metal triflate at a temperature and time sufficient to produce esters. The conversions of the reduction products of HMF to corresponding diesters can be quantitative with certain favored Lewis acids catalysts.